Interventional Studies
What are Clinical Trials?
Clinical trials are studies that test new medications in people. Doctors use clinical trials to discover new treatments for diseases. New treatments are possible only through the voluntary participation of patients and family members. Research and Clinical Trials opportunities may be available.
SUVEN
Study Title: SUVEN-502 Study
Purpose:
Individuals with Alzheimer's Disease are invited to participate in SUVEN-502 to determine the effectiveness of oral masupirdine, a medication targeting the serotonin system, and its ability to treat agitation associated with dementia of the Alzheimer's type compared to oral placebo. The study is 20 weeks long. In total, there will be 7 visits. Subjects will receive psychosocial support, undergo medical history, questionnaires/interviews related to agitation symptoms, cognitive assessments in addition to taking the oral medication and medication monitoring. Subjects will also need a study partner to participate in the study with them throughout the entire study.
(Principal Investigator: Pauline Wu, DO, Easton Center’s Katherine and Benjamin Kagan Alzheimer’s Disease Treatment Development Program)
For more information on how to participate in a study, please contact the Kagan Clinical Trials Program at (310) 794-6191 or send an email to EastonClinicalTrials@mednet.ucla.edu.
More information on the SUVEN study is available at clinicaltrials.gov ID#: NCT05397639.
BRAIN Trial
Study Title: BRAIN Trial (Brain Recovery And Individualized Neuromodulation)
Purpose
If you still have symptoms after your concussion, we are recruiting participants for a clinical trial funded by the Department of Defense that tests the benefits of personalized brain stimulation for chronic symptoms after concussion or mild traumatic brain injury (mTBI). We are recruiting individuals ages 18-65 who have sustained a concussion or mTBI in the last 3-24 months and are still experiencing symptoms. Each participant will undergo brain-mapping to find an overactive brain circuit that may be involved in symptoms. They may then receive stimulation to that circuit followed by MRIs and other testing to track symptom improvement.
(PI: Kevin Bickart, MD, PhD)
Contact: Email bickartlab@gmail.com or call (818) 392-4614 to participate or for more information.
More information on the BRAIN Trial is available at clinicaltrials.gov ID#: NCT06073886.
Brain Tau PET Histopathological Study
Study Title: An Open-label, Non-randomized, Multi-center Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of PET Imaging With [18F]PI-2620 for the Detection of Tau Deposition When Compared to Post-mortem Histopathology (ADvance).
Purpose
In this investigation, the drug [18F]PI-2620 is being tested for its usefulness in medical imaging studies to help look for a type of protein in the brain, called tau. [18F]PI-2620 is a compound with a low level of radioactivity attached, for use with positron emission tomography (PET), a type of medical test that resembles getting a CT or CAT scan. PET scanning enables us to see the presence, amounts and locations of certain types of molecules in the brain, and [18F]PI-2620 is being tested for its safety and accuracy in identifying and locating tau molecules. During this study participants will be asked to attend a screening visit to assess their health before receiving an injection of a small amount of [18F]PI-2620, a brain scan for 30 minutes, starting 45 minutes after receiving [18F]PI-2620, and a safety follow up phone call 7 days after the brain scan. Additionally, if any participants die in the months or years after undergoing the scan, their brain tissue will be autopsied and analyzed for presence, location and amounts of protein it may contain so that it can be compared to the PET scan results.
(PI: Daniel Silverman, MD, PhD)
Contact: Dr. Daniel Silverman at (310) 794-5067 to participate or for more information.
More information on the [18F]PI-2620 Phase 3 Histopathological study is available at clinicaltrials.gov ID#: NCT05641688.
LIFUP-MCIAD
Study Title: Modulating Memory with Low-Intensity Focused Ultrasound
Purpose
This clinical trial is sponsored by the National Institute on Aging and aims to assess the ability of low-intensity focused ultrasound pulsation (LIFUP) to affect the brain and potentially improve memory. We are recruiting individuals ages 50-90 with diagnosed or suspected mild cognitive impairment or mild Alzheimer’s Disease. Participation in the study involves receiving brain stimulation with LIFUP and completing memory tests, brain MRI scans, and a blood draw.
(PI: Taylor Kuhn, PhD, ABPP/CN)
Contact: Email tfus@mednet.ucla.edu to participate or for more information.
More information on the LIFUP-MCIAD study is available at clinicaltrials.gov ID#: NCT05417555.
PROMIS-AD
Study Title: Protocol for Maintaining and Improving Mental Status in Alzheimer’s Disease (PROMIS-AD) - a Pilot Study of Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer's Disease
Purpose
In this clinical trial, we are testing the effectiveness of repetitive Transcranial Magnetic Stimulation (TMS) on the treatment of Alzheimer’s Disease. We welcome English-speaking individuals age 60 to 100 years old with an Alzheimer’s diagnosis or probable Alzheimer’s to enroll. Participants will receive either active or sham TMS, and those who receive sham stimulation may be eligible to receive open-label active treatment after the completion of the study. Participation in the study would last up to 5 weeks for those receiving active stimulation and up to 10 weeks for those receiving sham.
(PI: Michael Leuchter, MD)
Contact: Cole Matthews at tmsresearch@mednet.ucla.edu or call (310) 825-4781 to participate or for more information.
More information on the PROMIS-AD study is available at clinicaltrials.gov ID#: NCT06597942.